IL1R1

Interleukin-1 receptor type 1

2,081 patent compounds predicted against IL1R1, 1,678 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL15289674	1.00	1/20
SCHEMBL5662375	0.68	1/20
SCHEMBL5226018	0.68	1/20
SCHEMBL2551781	0.67	1/20
SCHEMBL12091715	0.67	1/20
SCHEMBL14758394	0.67	1/20
SCHEMBL12091723	0.63	1/20
SCHEMBL12091706	0.61	1/20
SCHEMBL15085213	0.57	1/20
SCHEMBL11383783	0.55	1/20
SCHEMBL1039564	0.54	1/20
SCHEMBL1077253	0.53	1/20
SCHEMBL2548186	0.53	1/20
SCHEMBL6406524	0.53	1/20
SCHEMBL3871592	0.53	1/20
SCHEMBL15780987	0.53	1/20
SCHEMBL6748554	0.53	1/20
SCHEMBL12091703	0.53	1/20
SCHEMBL1077038	0.52	1/20
SCHEMBL12091852	0.52	1/20

Germline variants in IL1R1 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full IL1R1 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to IL1R1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
An Efficacy and Safety Study of GNR-086 (Canakinumab Biosimilar) and Ilaris® in Patients With Adult-onset Still's Disease	PHASE3	COMPLETED
Preoperative Glucocorticoid Use in Major Hepatectomy	PHASE2/PHASE3	COMPLETED
Early Phase Administration of Anakinra as a Rescue Treatment for Inhaled Allergen Challenge-Induced Airway Inflammation	PHASE1/PHASE2	WITHDRAWN
Late Phase Administration Anakinra as a Rescue Treatment for Inhaled Allergen Challenge-Induced Airway Inflammation	PHASE1/PHASE2	WITHDRAWN
Anti-inflammatory Therapy With Anakinra in Newly Diagnosed Type 1 Diabetes	PHASE1/PHASE2	COMPLETED
The Benefit of Bermekimab in Patients With Systemic Sclerosis	PHASE2	COMPLETED
Colchicine and Inflammation in Hemodialysis Patients	PHASE2	UNKNOWN
IL1-TRAP, Rilonacept, in Systemic Sclerosis	PHASE1/PHASE2	COMPLETED
Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction	PHASE2	COMPLETED
Interleukin-1 Receptor Antagonist and Insulin Sensitivity	PHASE2	UNKNOWN
Anakinra in Hidradenitis Suppurativa	PHASE2	COMPLETED
suPAR-guided Anakinra Treatment for Validation of the Risk and Management of Respiratory Failure by COVID-19 (SAVE)	PHASE2	COMPLETED
Rilonacept for Deficiency of the Interleukin-1 Receptor Antagonist (DIRA)	PHASE2	COMPLETED
Anakinra as a Rescue Treatment for Allergic Inflammation	PHASE1/PHASE2	WITHDRAWN
A Pilot, Prospective, Non-randomized Evaluation of the Safety of Anakinra Plus Standard Chemotherapy	PHASE1	COMPLETED
IL-1 Receptor Inhibitor for Granulomatous Complications in Patients With Chronic Granulomatous Disease	EARLY_PHASE1	COMPLETED
Assessment of Salivary GM-CSF, MIP, and IL-1β Levels in Subjects With Varying Periodontal Conditions	nan	RECRUITING
The Value of Interleukin-1β and Interleukin-33 Genetic Expression in the Pathogenesis and Differentiation of Primary ITP and SLE-Related Thrombocytopenia	nan	NOT_YET_RECRUITING
The Role of Toll-like Receptor-4 in Periodontitis Patients With End-stage Renal Disease in a Sample of Egyptian Population	nan	RECRUITING
Clinical Phenotypes in Pericarditis: IL-1RA Antibodies and suPAR Levels	nan	RECRUITING
Periduroscopy: Correlation Between the Outcome of Procedure and Histological-biochemical, Neuroinflammation and Genetic Factors.	nan	UNKNOWN
Interleukin-34 in Stage I and II Periodontitis	nan	COMPLETED
Probiotics and Systemic Inflammation in Patients With Metabolic Syndrome and High Cardiovascular Risk	nan	WITHDRAWN
The Mechanisms and Significances of Synergistic Effects of Mycophenolic Acid and LPS on IL-1β Secretion by Mononuclear	nan	UNKNOWN
The Role Of Neutrophil Proteases As Global Regulators Of Il-1 Family Cytokine Activity In Skin Disorders	nan	UNKNOWN
Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry Bad Cholesterol in the Blood	nan	COMPLETED
Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases (NOMID/CAPS, DIRA, CANDLE, SAVI, NLRC4-MAS, Still'S-like Diseases, and Other Undifferentiated Autoinflammatory Diseases)	nan	RECRUITING
Acupuncture for Reduction of Inflammation	nan	COMPLETED
Effects of Spinal Manipulative Treatment on Inflammatory Markers in Low Back Pain Patients	nan	COMPLETED
Effects of IL-1β and Its Receptor Antagonists in the Treatment of Severe Infection and Inflammatory Storm in Children	nan	WITHDRAWN

Related proteins — ESM-2 sequence neighbours (a IL1R1 binder may also engage these)

Protein	Name	Similarity
Q02955	—	0.996	Q02955 →
P13504	—	0.994	P13504 →
Q9NPH3	—	0.992	Q9NPH3 →
Q62929	—	0.991	Q62929 →
Q01638	—	0.989	Q01638 →
Q9HB29	—	0.988	Q9HB29 →
Q9ERS7	—	0.988	Q9ERS7 →
Q63621	—	0.987	Q63621 →
Q61730	—	0.985	Q61730 →
P59822	—	0.983	P59822 →
Q13478	—	0.983	Q13478 →
P14719	—	0.982	P14719 →
Q62611	—	0.982	Q62611 →
Q00560	—	0.978	Q00560 →
P16284	—	0.976	P16284 →
P30931	—	0.975	P30931 →
Q9EPQ1	—	0.975	Q9EPQ1 →
P21183	—	0.974	P21183 →
Q0ZUL9	—	0.973	Q0ZUL9 →
P51866	—	0.973	P51866 →
Q29612	—	0.973	Q29612 →
Q6GV17	—	0.973	Q6GV17 →
P40190	—	0.973	P40190 →
O95256	—	0.972	O95256 →
Q95242	—	0.972	Q95242 →
P43303	—	0.971	P43303 →
Q3SWT0	—	0.971	Q3SWT0 →
P27930	—	0.971	P27930 →
Q9BXR5	—	0.971	Q9BXR5 →
Q8N3J6	—	0.970	Q8N3J6 →